Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Patient Voice Missing In Asthma Drug Safety Debate – FDA’s Jenkins

Executive Summary

When a post-marketing safety signal arises, patients’ perspective of benefit is often drowned out by consumer advocates’ worries about a drug’s risks, the Office of New Drugs director says.

You may also be interested in...



Death Vs. Symptomatic Relief – Weighing Risks And Benefits For Asthma Drugs

When discussing a drug's benefits and risks, there is more to the equation than just death, Judith Kramer, Duke University, pointed out during a meeting of three FDA advisory committees to discuss asthma indications for long-acting beta agonists

FDA Panels Favor Advair, Symbicort Over Single-Entity LABAs For Asthma

Three FDA advisory committees recommended the withdrawal of asthma indications for two long-acting beta agonists - GlaxoSmithKline's Serevent (salmeterol) and Novartis's Foradil (formoterol) -during a Dec. 11 meeting

BrainStorm’s Phase III Data Do Not Support Clinical Benefit Of NurOwn In ALS, US FDA Says

Agency’s unusual public statement about an investigational product's development status may be aimed at countering bullish comments from the sponsor; FDA cites failure of pivotal trial on the primary and secondary endpoints and ‘modest excess in deaths’ with the cell therapy.

Topics

UsernamePublicRestriction

Register

OM008605

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel